Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Delivers On Authorized Xyrem In US

Also Strikes Deal With Junshi For Toripalimab In MENA Region

Executive Summary

Hikma has begun 2023 with the long-awaited launch of a US authorized generic version of Xyrem (sodium oxybate). Meanwhile, the company has also struck a deal with Junshi Biosciences for toripalimab in the MENA region.

You may also be interested in...



Hikma Continues To Mull Potential To Go Alone On Xyrem

Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.

Hikma Upgrades Full-Year Guidance For Generic And Branded Businesses

Hikma has provided a trading update in which it revised its expectations upwards for both its generic and branded business, while anticipating that its injectables unit will perform at the lower end of its current expectations.

Lupin Looks To Next Generation In Narcolepsy With Tentative US Xywav Nod

Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel